The Queensland Brain Institute under the University of Queensland has developed a remote care platform for monitoring and treating patients with neurological disorders.
WHAT IT DOES
Created in partnership with Neurosciences Queensland and Abbott Neuromodulation, the digital platform allows clinicians to remotely monitor patients and adjust their devices to treat and alleviate their symptoms in...
NeuroPace, maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, filed SEC documents yesterday outlining plans to raise as much as $75 million in an IPO listing on the Nasdaq.
The Mountain View, California-based company has been around since 1997 and has brought in a couple hundred million in funding across several rounds, according to CrunchBase. In fact, the...
NeuroPace, the maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, announced a $33 million equity raise on Monday. Accelmed Partners led the investment, which was joined by new backers such as Revelation Partners, Soleus Capital and an unnamed strategic investor. Prior backers KCK Group and OrbiMed Advisors also contributed.
Alongside the equity, NeuroPace...
Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s disease symptoms.
By now targeting the internal globus pallidus alongside the subthalamic nucleus and ventral intermediate nucleus, the company says that its system “is now the only directional DBS...
Halo Neuroscience, a device company that develops and sells the Halo Sport neurostimulation headset, announced yesterday that it has secured $13 million in Series B funding. Global private investment firm TPG led the round, which also had participation from prior investors Lux Capital, JAZZ Ventures Partners, and Xfund.
The Halo Sport headset connects to a paired mobile app to promote brain...
